Authors
Latest:
Daratumumab Regimen May Be the More Active Therapy Needed for AmyloidosisEfstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Latest:
Confronting Challenges and Embracing Progress in HER2+ Breast CancerYara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.
Latest:
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung CancerResearch shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Latest:
Company-wide Initiative Will Provide Standards for Collection and StorageThe Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Latest:
The Promise of ALLO-501A in Relapsed/Refractory LBCLMichael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.
Latest:
Eric Cheung: Competence and Compassion are Key to Earning Patients' TrustEric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and his patient-centered approach to care.
Latest:
HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging ApproachesPanelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.
Latest:
An Explosion of Agents for Myeloma TreatmentPrerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.
Latest:
Future Perspectives and Unmet Needs in the Treatment of Ovarian CancerChad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
Latest:
Olaparib Trial Supports 2-Year Treatment Duration in Ovarian CancerWilliam H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
Latest:
CAR T Benefits in Cancer Outweigh Potential Risk of Secondary MalignanciesMatthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.
Latest:
Addressing How to Treat Patients With Advanced Hepatocellular CarcinomaMehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Latest:
Expanding the Use of Targeted Therapies in GISTNeeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Latest:
Insights and Innovative Approaches to Addressing Disparities in Cancer CareCancer care disparities exist for underrepresented groups due to limited access to healthcare, clinical trials, and cultural barriers, but solutions like telemedicine and improved communication are emerging.
Latest:
Merryman Discusses the Role of MRD in Lymphoma Care and TrialsReid Merryman, MD, discusses which patients are typically monitored for minimal residual disease and whether there are specific subtypes or stages where the assessment is particularly critical.
Latest:
Niraparib Results Encourage Somatic Tumor Profiling in Ovarian CancerMatthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Latest:
A Deep Dive Into the Evolving Landscape of Prostate CancerIn season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Latest:
Challenges Remain in Treating Anaplastic Thyroid CancerYuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Latest:
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s MacroglobulinemiaChristian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Latest:
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Latest:
Questioning When to Start Immunotherapy for Patients With Oncogenic DriversKaren Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Latest:
Copanlisib and Rituximab Show Efficacy in Follicular LymphomaMark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Closing Perspectives on MM Treatment and CareBrea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
Transfusion Independence Serves as Key End Point for LR-MDS TrialsSaeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.
Latest:
Evaluating Key Challenges and Advancements in Prostate Cancer CareAlan H. Bryce, MD, discusses ongoing research in radioligand therapies.
